Saturday, March 28, 2009

Security lapses at Ayala Center, Makati, on March 28, 2009, At 2 entrances to SM Makati, at one entrance to Park Square 1. Etc.

Security lapses at Ayala Center, Makati, on March 28, 2009, At 2 entrances to SM Makati, at one entrance to Park Square 1.

Live moving insect fly dining area at SM food court at Ayala Center, Makati.

It will benefit buyers of camera phones with auto focus feature to, before buying said phones, ask the seller when the auto focus feature will fail.

Women and Heart Disease Prevention
http://www.cdc.gov/women/heart/index.htm

Tips to help you be a safe and healthy bride
http://www.cdc.gov/Features/HealthyBride/


* CDC Features

Here Comes the Bride: Healthy and Safe
As you plan your wedding day and new life together, don't forget to add health and safety to your “to do” list.



As you plan your wedding, make sure you make decisions that support your mental and physical health. Add to your “to do” list things to keep you safe and
healthy before and after the wedding. Learn tips to help you be a safe and healthy bride.

Promoting a Healthy Mind and Body

Make healthy choices to help you look and feel good, not only for your wedding, but also for a lifetime. Having a healthy body includes eating right,
getting at least 2½ hours of physical activity a week, and not smoking. Are you concerned about your weight? Achieve and maintain a healthy weight by
eating healthy, being active, and balancing the number of calories you consume with the number of calories your body uses. Avoid crash diets.

Planning a wedding and getting married can be stressful. Everyone has stress, but when stress makes us more likely to get sick, we need to pay attention.
Learn easy ways to manage stress, including getting enough sleep, setting limits, and relaxing.

Planning the Wedding and Other Events

There are many ways to make health a priority in planning the wedding and related events. Prepare or provide healthy meals, appetizers, snacks, drinks, and
desserts. Choose smoke-free venues. Reduce the likelihood of injury by choosing and placing decorations in such a way that they do not increase the risk
for falls, burns, or other types of injuries.

Preparing for Your Honeymoon

Whether it's by car, plane, train, ship or foot, take steps to stay safe and healthy during your honeymoon. Plan ahead. To lower your risk for illness and
injury, check health scores for cruise ships; learn about common diseases for the area if traveling abroad; get vaccinations; and pack and use sunscreen,
insect repellent, and appropriate safety gear for activities (such as helmets, life jackets, and knee pads).

Being True to Yourself

Ask yourself a few questions. Is there any abuse or violence in your relationship? Is anything interfering with your ability to be safe and healthy or
increasing your risk for disease or injury? Are you depressed or feeling anxious? See your health provider, a counselor, or others for help.


Women's Health

Safe and Healthy Bride



Say, "I do" to your health! Follow these tips to help you be a safe and healthy bride.
Eat healthy.

Make smart choices to help you look and feel good for your wedding, showers, parties, and new life together. Eat a variety of fruits and vegetables every
day.

Limit foods and drinks high in calories, sugar, salt, fat, and alcohol. Choose healthy snacks.

If you want to lose weight, eat smaller food portions, lower the amount of fat in your diet, and be active. Avoid crash dieting. Meet with your doctor or
nurse to talk about your best approach, especially if you have any health problems.

Include healthy meals and snacks for your guests. Add seasonal fruit or vegetables, low-fat snacks, and low-calorie drinks or desserts.

Healthy Weight

Nutrition for Everyone

Rethink Your Drink
Be active.

Be active for at least 2½ hours a week. Include activities that raise your breathing and heart rates and that strengthen your muscles. You don’t have to do
it all at once. Spread your activity out during the week, and break it into smaller chunks of time during the day.

How Much Physical Activity do Adults Need?
Be smoke-free.

Choose smoke-free venues for the wedding reception and other activities. Breathing in other people's smoke (secondhand smoke) causes health problems
similar to those of smokers.

Prepare for your new life together by quitting smoking. Quitting smoking has immediate and long-term benefits. Within 20 minutes after smoking that last cigarette, your body begins a series of positive changes that continue for years. Know that secondhand smoke causes health problems similar to those of smokers. Keep your home smoke-free.

Quit Smoking

Manage stress.

Trying to juggle wedding planning, work, school, and the other activities can be stressful. Early warning signs of stress include headache, sleep problems,
difficulty concentrating, short temper, upset stomach, job dissatisfaction, and low morale. Take steps to recognize and manage stress. Talk to your doctor
or nurse if you feel stressed or if you think you are losing control.

Stress at Work

Stress and Your Health: Frequently Asked Questions (HHS)

Style your hair with care.

If you’re changing hairstyles or hair color on your own, follow all directions, cautions, and warnings on hair products. Dyes and relaxers can hurt skin, hair, and eyes. Do a patch test before using dye on your hair. If a rash develops, don’t use the dye. Never dye eyebrows or eyelashes, as it might cause blindness. If in doubt, let the professionals do your hair.

Hair Dye and Hair Relaxers (FDA)

Test cosmetics and skin-care products before use.

Trying something new for your wedding? Test any new cosmetics or skin care products way before the wedding. For some people, using cosmetics like make-up
or deodorant may cause itching, redness, rash, sneezing, or wheezing. Allergies may happen the first time a product is used or after multiple uses. Always
test a product in a small area first. Follow all directions, cautions, and warnings on the label. Stop using the product if problems develop. Remove it
before bedtime to prevent skin and eye irritation.

Cosmetics (FDA)

Use Eye Cosmetics Safely

Prevent injury.


Wear comfortable shoes that won’t affect how you walk, stand, or dance. High heels may be in style, but they may also increase your chances of falling if
they’re too high, uncomfortable, or not something you usually wear.

Long dresses or trains should be comfortable to wear and not be a trip or fall hazard. Be aware of these issues when getting your dress fitted.

If you’re using candles at your wedding, ensure that they are placed properly so as not to burn anyone or set anything on fire. Place other decorations in
such a way so as not to increase the risk of injury.

If alcohol will be served at the wedding or other activities, be aware of how much you and others are drinking. Do not drink and drive. Encourage others to designate a sober driver before the event.

Injury Prevention and Control

Get a check-up.

Check with your doctor or nurse to see what tests and exams you need based on your age, sex, and health history. Regular health exams and tests can help
find problems before they start. They also can help find problems early, when your chances for treatment and cure are better. By getting the right health
services, screenings, and treatments, you are taking steps that help your chances for living a healthier life.

Talk to your doctor or nurse about preconception care and your and your partner’s family histories. Are there any issues that are of concern that both of
you need to discuss with your health care provider? Are there any issues that can potentially cause health problems if you decide to have children?

If you have a health problem, make sure you are taking steps to manage it. Don’t neglect your health while planning your wedding. Continue treatment plans
unless your doctor or nurse instructs you to do otherwise. Be sure to get any refills on prescription medications. Be realistic about what you can do.
Talk to your doctor or nurse if you have any questions.

Check-Up Checklist: Things to Do Before Your Next Check-Up

Family History: Resources and Tools

Preconception Care

Regular Checkups are Important
Get enough sleep.

Get 7-9 hours of sleep each night. How you feel and perform during the day is related to how much sleep you get the night before. If sleepiness interferes
with your daily activities, more sleep each night will improve the quality of your waking hours.

Sleep and Sleep Disorders

Sleep and Sleep Disorders: A Public Health Challenge
Be true to yourself.

Being a bride and having a great wedding are two things some women dream about. There is sometimes a mix of reality and fantasy in thinking about being a
bride and wife. After the honeymoon, life and marriage may not live up to the expectations.

Determine if you have realistic expectations of what marriage will be like and what your and your partner’s roles are. Do you or your partner behave in
ways that may not demonstrate a healthy relationship? Have you or your partner verbally, emotionally, or physically abused the other? Are there things
about your partner or relationship that make you uncomfortable? Several factors can increase the risk that someone will hurt his or her partner. Talk to
your doctor, nurse, counselor, or someone else you trust if you need help.

If you are a victim of intimate partner violence, contact your local battered women's shelter.


Intimate Partner Violence

Sexually Transmitted Diseases
Travel safely.

If you’re taking a cruise, know your ship’s recent inspection scores. If you're traveling internationally, make sure you have all the vaccinations
required for that area. Always wear your seatbelt while riding in a motor vehicle. Protect yourself from sunburn, mosquitoes, and ticks.

Fight the Bite: West Nile Virus

Protect Yourself from the Sun

Stop Ticks

Travelers’ Health

Go green.

Recycle all the magazines you read while preparing for the wedding. Consider using favors, utensils, decorations, and accessories that can be easily
recycled or reused.

Three R’s of Going Green: Reduce, Reuse, Recycle.

Content Source: CDC Office of Women's Health
Page last modified: March 23, 2009
Page last reviewed: March 20, 2009


hubblesite
http://hubblesite.org/

Nearly 400 years after Galileo first observed the heavens through a telescope, we continue to seek answers to age-old questions about the universe. And while the technology has evolved over the centuries, the inquiry remains essentially the same: What's out there, where did it come from, and what does it mean?

At the Space Telescope Science Institute (STScI), we're working hard to study and explain the once-unimaginable celestial phenomena now made visible using Hubble's cutting-edge technology. In the course of this exploration we will continue to share with you the grace and beauty of the universe, because the discoveries belong to all of us.

Probe deeper! Explore the following links to learn more about who we are and what we do.

If you are visiting the Baltimore/Washington area, make it a point to come to our monthly Hubble Public Talks and learn about Hubble's latest discoveries first-hand.

HubbleSite is produced by the Space Telescope Science Institute's Office of Public Outreach.

Wednesday, March 25, 2009

Security lapses occurred on March 25, 2009 at entrances To Robinsons Ermita, Harrison Plaza mall, The Landmark building at Ayala Center, Makati City.;

Security lapses occurred on March 25, 2009 at entrances To Robinsons Ermita, Harrison Plaza mall, The Landmark building at Ayala Center, Makati City.

customer advisory re McDonald's restaurant
which was at the Landmark building, Ayala Center, Makati city. On March 25, 2009, I was at said restaurant and I saw what were identified as toys being
offered for sale. I am willing to execute an affidavit as to what I saw. Did the Bureau of Food or the Department of Trade and Industry certify that said
objects are safe for children?

Advisory re the Manager - SM Supermarket Makati branch, Ayala Center, Makati City.
A senior citizen received a letter identified as sent by said manager, who was identified as Lilibeth Sayo Store Manager of said SM Supermarket.
Said letter contained the following words: "In response to your letter through DTI . . . re incorrect amount of change last August 4, 2008 from our former
cashier Ms. Medina Corpuz, we did try to reach the said personnel but we were not able to, since she has been disconnected from employment with us prior to
receiving your letter" Said allegation is not credible. The fact is that shortly after said shortchanging to said senior citizen, by said Corpuz, of one
hundred pesos, said senior citizen called for someone from Customer Service. In response, a person (apparently a woman) came to said Corpuz. Said senior
citizen witnessed that said Customer Service representative told said Corpuz words to the effect that she should count the paper money. Then said senior
went to the Customer Service and submitted a written complaint vs. said Corpuz, A person accepted said written complaint but refused to acknowledge to
said senior citizen in writing that she received said written complaint. So, on said date, customer service became aware of said shortchanging by said
Corpuz.

National Atlas of the United States
http://www-atlas.usgs.gov/

United States Department of Agricuture Food Safety and Inspection Service FSIS Recalls
http://www.fsis.usda.gov/Fsis_Recalls/Recall_Case_Archive/index.asp

United States Department of Agricuture Food Safety and Inspection Service FSIS Recalls
http://www.fsis.usda.gov/Fsis_Recalls/Recall_Case_Archive/index.asp

Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- February 2009
http://www.fda.gov/medwatch/safety/2009/feb09_quickview.htm

NIH Health Topic Update: High Blood Pressure
Tuesday, March 24, 2009 1:11 AM
http://health.nih.gov/topic/HighBloodPressure

National Institutes of Health information re pregnancy
http://health.nih.gov/topic/Pregnancy

NICHD
Eunice Kennedy Shriver National Institute of Child Health and Human Development

* Am I at Risk for Gestational Diabetes?
* High-Risk Pregnancy
* Managing Gestational Diabetes: A Patient's Guide to a Healthy Pregnancy
* Preconception Care
* Preeclampsia and Eclampsia
* Pregnancy
* Reproductive Health
* Research on Pregnancy and Birth

contact number Call (800) 370-2943 for more information
NCI
National Cancer Institute

* Breast Cancer and Pregnancy Spanish / English
* PDQ-Treatment-Patients: Breast Cancer and Pregnancy

contact number Call (800) 422-6237 for more information
NIAAA
National Institute on Alcohol Abuse and Alcoholism

* Drinking and Your Pregnancy [ PDF Version ]

NIAMS
National Institute of Arthritis and Musculoskeletal and Skin Diseases

* Pregnancy, Breastfeeding, and Bone Health [ PDF Version ]

contact number Call (877) 22-NIAMS or (301) 495-4484 for more information
NIDDK
National Institute of Diabetes and Digestive and Kidney Diseases

* Embarazo, parto y control de la vejiga Spanish
* Fit for Two Tips for Pregnancy
* Fit for Two--Tips for Pregnancy (Spanish) Spanish
* Pregnancy, Childbirth, and Bladder Control PDF

NIEHS
National Institute of Environmental Health Sciences

* Caffeine

NIMH
National Institute of Mental Health

* Stopping Antidepressant Use While Pregnant May Pose Risks
* Summit on Women and Depression: Proceedings and Recommendations PDF

contact number Call (301) 443-4513 for more information
ODS
Office of Dietary Supplements

* Dietary Supplement Fact Sheet: Folate

contact number Call (301) 435-2920 for more information
Related Topics

* AIDS and Pregnancy
* High Risk Pregnancy
* Pregnancy and Substance Abuse
* Pregnancy Loss
* Prenatal Care
* Teenage Pregnancy
* Reproduction and Sexual Health
* Women's Health


On This Page:

Clinical Trials Information
The NIH funds research studies that you may be able to join. Visit clinicaltrials.gov for a list of ongoing clinical trials.
Research Advances

* Experimental Vaccine Shows Promise in Preventing Cytomegalovirus Infection
* Combination of Genes and Prenatal Exposure to Smoking Increases Teens’ Risk of Disruptive Behavior
* Low Levels of Vitamin B12 May Increase Risk for Neural Tube Defects

This page was last reviewed on Wednesday, March 04, 2009.

Monday, March 23, 2009

March 23, 2009 security lapse at entrance to Robinsons Ermita; advisory re Wendy's restaurant at Robinsons Ermita; advisory re Rissa M. Mananquil; etc

Security lapse on March 23, 2009 at entrance to Robinsons Ermita.
Because of said security lapse, I could have brought dangerous weapons into said mall.

Advisory re Wendy's restaurant at Robinsons Ermita
On March 23, 2009, I was at said restaurant. I saw a live moving fly in the dining area of said restaurant.

advisory re Rissa M. Mananquil, Tricks Exfocleanser, L'Oreal skincare line Men's Expert

The following words were published under said Mananquil's name in the March 4, 2009 issue of the Philippine Star newspaper: "I recommend Tricks Exfocleanser", My comments: If people follow said Mananquil's recommendation regarding said product and are not satisfied with said product, will she help them get refunds? "Tricks Exfocleanser is especially formulated for men and effective enough to address your needs in caring for the face." My comments: Did said Mananquil actually witness the formulation of said product? If said product is not effective enough to address said John's needs in caring for the face, will said Mananquil help said John?"Product description explains . . ." My comment: Is said Mananquil naive enough to believe a product description? "Tricks Exfocleanser is dermatologist tested" My comment: Did said Mananquil witness said testing by said alleged dermatologist? "its also enriched with vitamins E, B3, and B5 to nourish the skin." My comment: Does said Mananquil have personal knowledge of said alleged enrichment? "Pimple Clearing (controls breakouts)" My comment: If said product called pimple clearing does not control breakouts, will said Mananquil help customers who may have used said product? "Oil Control (gets rid of excess oil" My comment: If said alleged Oil Control product does not get rid of excess oil, will said Mananquil help customers who may have used said product? "Whitening (lightens skin)" My comment: If said so called Whitening product does not lighten skin will said Mananquil help customers who may have used said product?
Said Mananquil also made the following claims regarding the L'Oreal skincare line Men's Expert: "This , , , skin care line offers . . . with sun
protection." My comment: What, if any, is the basis of said Mananquil's claim that said products have sun protection? " :L'Oreal Men's Expert White
Activ . . . is a moisturizer with UV protection that will help give you clearer and brighter skin."


U.S. Food and Drug Administration Center for Drug Evaluation and Research Office for Nonprescription Products
http://www.fda.gov/cder/offices/OTC/default.htm

What We Do

Over-the-counter (OTC) drug products are those drugs that are available to consumers without a prescription. There are more than 80 classes (therapeutic categories) of OTC drugs, ranging from acne drug products to weight control drug products. As with prescription drugs, CDER oversees OTC drugs to ensure that they are properly labeled and that their benefits outweigh their risks.

OTC drugs play an increasingly vital role in America's health care system by providing easy access to certain drugs that can be used safely without the help of a health care practitioner. This enables consumers to take control of their own health care in many situations. There are more than 100,000 OTC drug products marketed, encompassing about 800 significant active ingredients.

Most OTC drug products have been marketed for many years, prior to the laws that require proof of safety and effectiveness before marketing. For this reason, FDA has been evaluating the ingredients and labeling of these products as part of "The OTC Drug Review Program." The goal of this program is to establish OTC drug monographs for each class of products.

OTC drug monographs are a kind of "recipe book" covering acceptable ingredients, doses, formulations, labeling, and testing. OTC drug monographs are continually updated to add additional ingredients and labeling as needed. Products conforming to a monograph may be marketed without FDA pre-approval, while those that do not, must undergo separate review and approval through the New Drug Application (NDA) process. The NDA process, and not the monograph process, is also used for new ingredients entering the OTC marketplace for the first time. For example, the newer OTC drug products (previously available only by prescription) are first approved through the NDA process and their "switch" to OTC status is approved via the NDA process.

FDA's review of OTC drugs is primarily handled by CDER's Office of Nonprescription Products. However, scientists and regulators throughout CDER, the Office of General Counsel, and other Centers within FDA are routinely asked to assist in this massive effort. There is also an advisory committee, the "Nonprescription Drug Advisory Committee," which meets regularly to assist the agency in evaluating issues surrounding these products.

Date updated: May 29, 2003



Office of Nonprescription Products
Consumer Information: Safe Use of Over-the-Counter Drug Products
General Information

* Medicines In My Home. An educational program about safe use of OTC medicines.
* Over-the-Counter Medicine. These materials will help you, working with your health care professionals, to choose and use over-the-counter medicine wisely.
* Over-the-Counter Medicine: All graphics and other media. These materials include brochures, pamphlets, public service announcements, and more.
* FDA Consumer Health Information
* Frequently Asked Questions on the Regulatory Process of OTC Drugs
* How FDA Regulates OTC Drugs
* New Drug Development in the U.S.


http://www.fda.gov/cder/drug/infopage/sunscreen/qa.htm#7
Questions and Answers on the 2007 Sunscreen Proposed Rule

1. What is ultraviolet light and why should I be concerned about it?
2. Why is FDA now coming up with ratings for UVA protection provided by sunscreens and how are these ratings different than Sun Protection Factor (SPF) ratings?
3. Is the 1999 rule currently in effect? How does this proposed rule relate to the 1999 final rule?
4. What’s being proposed in this new rule?
5. What does the proposed labeling look like?
6. Why are sunscreens limited to SPFs of “50+?”
7. How will consumers know how much UVA protection a sunscreen provides?
8. Why is FDA proposing symbols and descriptors to identify the level of UVA protection rather than numerals similar to the SPF?
9. Have star ratings for UVA protection been used before?
10. What type of testing is required to demonstrate UVA protection?
11. How long is the comment period and where should I send comments?
12. Can sunscreens prevent skin cancer?
13. What has changed about the sun alert statement and why did we change it?
14. Why is it important to reapply sunscreens frequently?
15. Are sunscreens really “waterproof?”
16. Are sunscreens and “sunblocks” the same thing?
17. I understand that this proposed rule introduces UVA testing. Have any changes been made to the SPF (UVB) test method?
18. Do manufacturers have to comply with the regulations in this proposed rule?
19. When will FDA publish a final rule based on this proposed rule?
20. Sunscreens are considered cosmetics in Europe. Why are sunscreens regulated as drugs in this country?
21. Where can I get more information about sunscreens?



1. What is ultraviolet light and why should I be concerned about it?

The sun produces not only the visible light that we can see but also ultraviolet (UV) light that we can’t see. There are two types of UV light that can be harmful to us: UVA and UVB. UVB light is primarily responsible for causing sunburn. Both UVB and UVA light contribute to skin cancer, premature skin aging, and other types of skin damage. It is important to protect ourselves from both UVB and UVA light.

2. Why is FDA now coming up with ratings for UVA protection provided by sunscreens and how are these ratings different than SPF ratings?

FDA has been concerned about exposure to ultraviolet (UV) light from the sun since the OTC drug review process began over 30 years ago. Until now most of the focus of FDA’s attention has been on reducing exposure to UVB light. Nonetheless, the issue of protecting against exposure to UVA light has been addressed broadly in all previous rulemakings. Currently, there are no internationally accepted standards for evaluating the effectiveness of a sunscreen in protecting against UVA light. In fact, only a few countries have even addressed UVA protection at all. FDA is aware of ten different tests designed to measure UVA protection. Over the last several years, FDA has conducted detailed analyses of data and information related to all of these UVA tests and, in this rule, is proposing a standard testing protocol. The new protocol requires clinical and non-clinical tests to give an accurate and reproducible assessment of UVA protection. Comparable to the SPF test which measures how well a sunscreen reduces burning, the clinical test for UVA effectiveness measures how well a sunscreen reduces darkening of the skin. Based on this test, sunscreens are classified as low, medium, high, or highest UVA protection. The non-clinical test measures the ability of a sunscreen to reduce the amount of UVA light passing through the sunscreen. Based on the non-clinical test, sunscreens are also classified as providing low, medium, high, or highest UVA protection. The results of both tests are combined to produce a single UVA protection level (i.e., low, medium, high, or highest) with a corresponding star rating. The UVA protection level represents the lowest level of protection determined by the two tests. For example, if one test indicates a low level of UVA protection and the other test indicates a medium level of protection, the sunscreen is labeled as having a low level of UVA protection.

The level of UVB sunscreen protection is indicated by a numerical value (e.g., SPF 30). In contrast, the level of UVA protection is indicated by a descriptor with an accompanying star rating (e.g., medium 2 stars - medium). FDA believes the different ways of labeling UVB and UVA protection will minimize potential confusion about the ratings.

3. Is the 1999 rule currently in effect? How does this proposed rule relate to the 1999 final rule?

The 1999 final rule addressed UVB testing and labeling requirements for sunscreen products. That final rule was stayed and is not currently in effect so that the agency could also address UVA testing and labeling requirements for sunscreen products. This proposed rule amends the conditions of the final rule to incorporate these UVA testing and labeling requirements. After consideration of the comments submitted in response to this proposed rule, FDA will then issue a final rule that addresses both the UVA and UVB issues for sunscreen products.

4. What’s being proposed in this new rule?

FDA is proposing to:

* add new combinations of avobenzone and other active ingredients
* include UVA protection effectiveness testing and corresponding labeling
* change the highest SPF values from “30+” to “50+”
* require a revised “sun alert” statement as the first statement in the Drug Facts Warnings section (the original statement was optional)
* place greater emphasis on reapplying sunscreens (to avoid lowering protection)
* make minor revisions to the existing SPF (UVB) testing procedures



5. What does the proposed labeling look like?

For a three-ingredient, very water resistant sunscreen, the principal display panel will look something like this:

sunscreen - proposed label


For a three-ingredient, very water resistant sunscreen, the Drug Facts box will look like this:

Sunsceen - Proposed Drug Facts

6. Why are sunscreens limited to Sun Protection Factors ( SPF) of “50+?”

FDA limits SPF values based on data demonstrating that the SPF test provides accurate and reproducible results. When FDA published the sunscreen final monograph in 1999, FDA had only received data demonstrating that the SPF test produces accurate and reproducible data for sunscreens with SPF values as high as 30. Since publication of the final monograph, FDA has received data indicating that sunscreens with SPF values as high as 50 can be measured accurately and reproducibly using the SPF test. Further, FDA believes that, although we have not yet seen such data, some sunscreens may produce SPF values greater than 50. For such sunscreens, we are allowing an SPF of “50+.” If FDA receives data that support accurate testing of sunscreens higher than 50, we will consider revising the upper limit of SPF permitted in labeling.

7. How will consumers know how much UVA protection a sunscreen provides?

FDA is proposing to use symbols (stars) along with descriptors (low, medium, high, or highest) to indicate how much UVA protection a sunscreen provides. Sunscreens providing UVA protection will bear one of the following configurations:
Star Category

Category Descriptor
sunscreen 1 star low

Low
sunscreen category: 2 stars medium

Medium
sunscreen category: 3 stars high

High
sunscreen category: 4 stars highest

Highest

So a sunscreen providing medium UVA protection may be labeled like this:

UVA
sunscreen category: 2 stars medium
Medium

If a sunscreen hasn’t been shown to provide any UVA protection, FDA proposes that the sunscreen contain the statement “No UVA Protection” near the SPF value.



8. Why is FDA proposing symbols and descriptors to identify the level of UVA protection rather than numerals similar to the SPF?

Because SPF values have been used in the United States for more than three decades, consumers are familiar with SPF numbers and know how to select the appropriate sunscreen based on the SPF value. Therefore, FDA does not believe the SPF numerical values should be changed. However, FDA believes consumers might be confused if UVB and UVA protection levels were both identified by numbers. Having distinct ways of identifying UVB and UVA protection levels should make it less likely that consumers will confuse the two ratings. Although the symbol and descriptor rating of UVA protection is new, FDA expects consumers will learn how to use this information to select the appropriate sunscreen, as they have done with SPF values. FDA believes consumers are familiar with star rating because they are used to rate the quality of a variety of topics (e.g., movies, hotels, and restaurants).

9. Have star ratings for UVA protection been used before?

Yes. In January 1992, the Boots Co. in the United Kingdom developed a star rating system to characterize UVA protection. Protection ratings range from “minimum” (one star) to “ultra” (five stars). In addition, although star ratings have not previously been used in the Unites States to rate UVA protection levels, they have been used extensively to rate many industries (e.g., movies, hotels, and restaurants).

10. What type of testing is required to demonstrate UVA protection?

Two separate tests must be conducted to demonstrate that a sunscreen helps provide protection against UVA light. One of these is an in vitro test (performed on a quartz plate) and the other is an in vivo test (performed on humans). The results of both tests are combined to produce a single UVA protection level (i.e., low, medium, high, or highest). The UVA protection level represents the lowest level of protection determined by the two tests. For example, if one test indicates a low level of UVA protection and the other test indicates a medium level of protection, the sunscreen is labeled as having a low level of UVA protection.

The in vitro test is a non-clinical test, meaning it is performed in a laboratory and not on humans. This test measures the ability of a sunscreen to reduce the amount of UVA radiation passing through the sunscreen. The in vivo test is performed on humans and is similar to the SPF test. The major difference between this test and the SPF test is that sunburn is measured in the SPF test and skin darkening is measured in this test.

11. How long is the comment period and where should I send comments?

Before finalizing any monograph, FDA allows the public to share its views (comments) on the proposed regulations. For most of the issues in this proposed rule, FDA is accepting comments for 90 days from the date the proposed rule published.

Comments must be identified with “Docket No. 1978N-0038” and can be submitted electronically or in written form:

Electronic submissions

* Federal eRulemaking Portal: http://www.regulations.gov
* FDA web site: http://www.fda.gov/dockets/ecomments

Written submissions

* FAX: 301-827-6870
* Mail/Hand Delivery/Courier:
Division of Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm. 1061
Rockville, MD 20852



12. Can sunscreens prevent skin cancer?

FDA doesn’t have any data directly linking the use of sunscreens to a reduction in the risk of developing skin cancer. Research has shown that UV exposure increases skin cancer, premature skin aging (e.g., wrinkles), and other skin damage (e.g., sunburn). Although studies have shown that limiting time in the sun, wearing protective clothing, and using sunscreens decrease UV exposure, studies have not specifically linked the use of sunscreen by itself to reduced risk of skin cancer or skin aging. To the contrary, studies have shown that some consumers increase time in the sun when wearing sunscreens, thereby increasing UV exposure. Thus, in this proposed rule, FDA proposes that the following statement be required in the Warnings section of the Drug Facts box:

UV exposure from the sun increases the risk of skin cancer, premature skin aging, and other skin damage. It is important to decrease UV exposure by limiting time in the sun, wearing protective clothing, and using a sunscreen.

13. What has changed about the sun alert statement and why did we change it?

The sun alert statement used to be optional and, if included, appeared in the Other information section of the Drug Facts box or outside the Drug Facts box altogether. The statement read, “Sun alert: Limiting sun exposure, wearing protective clothing, and using sunscreens may reduce the risks of skin aging, skin cancer, and other harmful effects of the sun.” FDA now proposes to require a modified version of the sun alert statement be included as the first statement under Warnings in the Drug Facts box. The new statement reads:

UV exposure from the sun increases the risk of skin cancer, premature skin aging, and other skin damage. It is important to decrease UV exposure by limiting time in the sun, wearing protective clothing, and using a sunscreen.

14. Why is it important to reapply sunscreens frequently?

There are three reasons why sunscreens should be reapplied frequently. First, sunscreens can be physically rubbed off. For example, drying off with a towel can remove sunscreen from the skin. Second, sunscreens can be washed off when swimming or with heavy sweating. No sunscreens are truly “waterproof” or “sweatproof.” Third, some of the active ingredients in sunscreens start to break down over time. This break down can be accelerated by sun exposure. These three factors can prevent sunscreens from providing the level of protection indicated by the SPF and or UVA values. Thus, to ensure that sunscreens provide effective prevention, FDA proposes that sunscreens include the following directions:

* For sunscreens that are not water resistant:
o “Reapply at least every 2 hours and after towel drying, swimming, or sweating”
* For sunscreens that are water resistant:
o “Reapply after 40 minutes of swimming or sweating, and after towel drying. Otherwise, reapply at least every 2 hours."

15. Are sunscreens really “waterproof?”

No. FDA has determined that sunscreens are neither sweatproof nor waterproof. Most sunscreen formulations don’t dissolve in water (or sweat), but can be washed off during swimming and as a consequence of sweating. Thus, FDA does allow claims that sunscreens are water resistant or water/sweat resistant if the sunscreens retain the label SPF and /or UVA protection values following 40 minutes of water immersion. Sunscreens that retain the label SPF and/or UVA protection values after 80 minutes of water immersion can be identified as “very water resistant” or “very water/sweat resistant.”

You may see sunscreen products marketed as “waterproof” or “sweatproof.” FDA does not believe that these are accurate statements and explained this position in both the tentative final monograph published in 1993 and the final monograph published in 1999. When FDA publishes a sunscreen final rule that includes both UVB and UVA testing and labeling requirements, manufacturers will be required to amend these claims.

16. Are sunscreens and “sunblocks” the same thing?

FDA does not believe the term “sunblock” is accurate. No sunscreen completely blocks UV rays. FDA believes the term “sunscreen” more accurately describes the action of this type of drug product.



17. Have any changes been made to the SPF (UVB) test method?

Yes. FDA is proposing changes to the SPF test method. FDA believes these changes will decrease the health risk to persons enrolled in the SPF test. The changes also should lead to more accurate and reproducible results. The changes will not alter how consumers compare sunscreens with different SPF values to select the appropriate product. The changes will only alter how manufacturers determine the SPF values of these products.

18. Do manufacturers have to comply with the regulations in this proposed rule?

When the final rule is published, manufacturers will be required to comply with sunscreen regulations. Until then, FDA strongly encourages manufacturers to comply with this proposed rule. We believe that compliance with this proposed rule is in the best interests of public health. Nonetheless, manufacturers are not required to comply with the proposed regulations until FDA publishes a final rule

19. When will FDA publish a final rule based on this proposed rule?

Following publication of this proposed rule in the Federal Register, there is a 90-day comment period allowing any interested parties to recommend changes to the proposed rule. After the comment period ends, FDA will review all of the submitted data and information. FDA will then issue a final rule for OTC sunscreens, which will take effect on a date specified in the final rule. After that date all OTC sunscreen manufacturers must comply with the final rule. FDA will work as quickly as possible to draft the final rule.

20. Sunscreens are considered cosmetics in Europe. Why are sunscreens regulated as drugs in this country?

This issue was addressed in the 1999 sunscreen final rule (Federal Register, vol. 64, pages 27668 – 27669). In that document, we noted that because sunscreen active ingredients “affect the structure and function of the body by absorbing, reflecting, or scattering the harmful, burning rays of the sun,” sunscreen products intended for such use are regulated as drugs under section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (21 USC 321(g)(1)). Although the European Commission classifies sunscreens as cosmetics, sunscreens in Europe must meet standards for safety and effectiveness comparable to the sunscreen (drug) standards that exist in the United States.

21. Where can I get more information about sunscreens?

Visit FDA’s website for nonprescription drug products: http://www.fda.gov/cder/Offices/OTC/consumer.htm


http://www.fda.gov/cder/Offices/OTC/understanding_spf_sunscreen.htm
Sunburn Protection Factor (SPF)

SPF is a measure of how much solar energy (UV radiation) is required to produce sunburn on protected skin (i.e., in the presence of sunscreen) relative to the amount of solar energy required to produce sunburn on unprotected skin. As the SPF value increases, sunburn protection increases.

There is a popular misconception that SPF relates to time of solar exposure. For example, many consumers believe that, if they normally get sunburn in one hour, then an SPF 15 sunscreen allows them to stay in the sun 15 hours (i.e., 15 times longer) without getting sunburn. This is not true because SPF is not directly related to time of solar exposure but to amount of solar exposure. Although solar energy amount is related to solar exposure time, there are other factors that impact the amount of solar energy. For example, the intensity of the solar energy impacts the amount. The following exposures may result in the same amount of solar energy:

* one hour at 9:00 a.m.
* 15 minutes at 1:00 p.m.

Generally, it takes less time to be exposed to the same amount of solar energy at midday compared to early morning or late evening because the sun is more intense at midday relative to the other times. Solar intensity is also related to geographic location, with greater solar intensity occurring at lower latitudes. Because clouds absorb solar energy, solar intensity is generally greater on clear days than cloudy days.

In addition to solar intensity, there are a number of other factor that influence the amount of solar energy that a consumer is exposed to:

* skin type
* amount of sunscreen applied
* reapplication frequency

Fair-skinned consumers are likely to absorb more solar energy than dark-skinned consumers under the same conditions. The amount of sunscreen applied also impacts the amount of solar radiation absorbed, because more sunscreen results in less solar energy absorption. Because sunscreens wear off and become less effective with time, the frequency with which they are reapplied is critical to limiting absorption of solar radiation. The reapplication frequency is also impacted by the activities that consumers are involved in. For example, consumers who swim while wearing sunscreen need to reapply the sunscreen more frequently because water may wash the sunscreen from the body. In addition, high levels of physical activity require more frequent reapplication because the activity may physically rub off the sunscreen and heavy sweating may wash off the sunscreen. In general, more frequent reapplication is associated with decreased absorption of solar radiation.

Because of the various factors that impact the amount of solar radiation, SPF does not reflect time in the sun. In other words, SPF does not inform consumers about the time that can be spent in the sun without getting sunburn. Rather, SPF is a relative measure of the amount of sunburn protection provided by sunscreens. It allows consumers to compare the level of sunburn protection provided by different sunscreens. For example, consumers know that SPF 30 sunscreens provide more sunburn protection than SPF 8 sunscreens.



NINDS Traumatic Brain Injury Information Page
http://www.ninds.nih.gov/disorders/tbi/tbi.htm

Synonym(s): Head Injury, Brain Injury
Condensed from Traumatic Brain Injury: Hope Through Research

Table of Contents
What is Traumatic Brain Injury?
Is there any treatment?
What is the prognosis?
What research is being done?
Clinical Trials
Organizations
Related NINDS Publications and Information
Publicaciones en Español
Additional resources from MEDLINEplus

What is Traumatic Brain Injury?

Traumatic brain injury (TBI), also called acquired brain injury or simply head injury, occurs when a sudden trauma causes damage to the brain. TBI can result when the head suddenly and violently hits an object, or when an object pierces the skull and enters brain tissue. Symptoms of a TBI can be mild, moderate, or severe, depending on the extent of the damage to the brain. A person with a mild TBI may remain conscious or may experience a loss of consciousness for a few seconds or minutes. Other symptoms of mild TBI include headache, confusion, lightheadedness, dizziness, blurred vision or tired eyes, ringing in the ears, bad taste in the mouth, fatigue or lethargy, a change in sleep patterns, behavioral or mood changes, and trouble with memory, concentration, attention, or thinking. A person with a moderate or severe TBI may show these same symptoms, but may also have a headache that gets worse or does not go away, repeated vomiting or nausea, convulsions or seizures, an inability to awaken from sleep, dilation of one or both pupils of the eyes, slurred speech, weakness or numbness in the extremities, loss of coordination, and increased confusion, restlessness, or agitation.

Is there any treatment?

Anyone with signs of moderate or severe TBI should receive medical attention as soon as possible. Because little can be done to reverse the initial brain damage caused by trauma, medical personnel try to stabilize an individual with TBI and focus on preventing further injury. Primary concerns include insuring proper oxygen supply to the brain and the rest of the body, maintaining adequate blood flow, and controlling blood pressure. Imaging tests help in determining the diagnosis and prognosis of a TBI patient. Patients with mild to moderate injuries may receive skull and neck X-rays to check for bone fractures or spinal instability. For moderate to severe cases, the imaging test is a computed tomography (CT) scan. Moderately to severely injured patients receive rehabilitation that involves individually tailored treatment programs in the areas of physical therapy, occupational therapy, speech/language therapy, physiatry (physical medicine), psychology/psychiatry, and social support.
What is the prognosis?

Approximately half of severely head-injured patients will need surgery to remove or repair hematomas (ruptured blood vessels) or contusions (bruised brain tissue). Disabilities resulting from a TBI depend upon the severity of the injury, the location of the injury, and the age and general health of the individual. Some common disabilities include problems with cognition (thinking, memory, and reasoning), sensory processing (sight, hearing, touch, taste, and smell), communication (expression and understanding), and behavior or mental health (depression, anxiety, personality changes, aggression, acting out, and social inappropriateness). More serious head injuries may result in stupor, an unresponsive state, but one in which an individual can be aroused briefly by a strong stimulus, such as sharp pain; coma, a state in which an individual is totally unconscious, unresponsive, unaware, and unarousable; vegetative state, in which an individual is unconscious and unaware of his or her surroundings, but continues to have a sleep-wake cycle and periods of alertness; and a persistent vegetative state (PVS), in which an individual stays in a vegetative state for more than a month.
What research is being done?

The National Institute of Neurological Disorders and Stroke (NINDS) conducts TBI research in its laboratories at the National Institutes of Health (NIH) and also supports TBI research through grants to major medical institutions across the country. This research involves studies in the laboratory and in clinical settings to better understand TBI and the biological mechanisms underlying damage to the brain. This research will allow scientists to develop strategies and interventions to limit the primary and secondary brain damage that occurs within days of a head trauma, and to devise therapies to treat brain injury and improve long-term recovery of function.

More information about Traumatic Brain Injury (TBI) Research is available at http://www.ninds.nih.gov/research/tbi/index.htm


Organizations
Acoustic Neuroma Association
600 Peachtree Parkway
Suite 108
Cumming, GA 30041
info@anausa.org
http://www.anausa.org
Tel: 770-205-8211 877-200-8211
Fax: 770-205-0239/877-202-0239

Brain Injury Association of America, Inc.
1608 Spring Hill Rd
Suite 110
Vienna, VA 22182
braininjuryinfo@biausa.org
http://www.biausa.org
Tel: 703-761-0750 800-444-6443
Fax: 703-761-0755

Brain Trauma Foundation
523 East 72nd Street
8th Floor
New York, NY 10021
http://www.braintrauma.org
Tel: 212-772-0608
Fax: 212-772-0357

Family Caregiver Alliance/ National Center on Caregiving
180 Montgomery Street
Suite 1100
San Francisco, CA 94104
info@caregiver.org
http://www.caregiver.org
Tel: 415-434-3388 800-445-8106
Fax: 415-434-3508

National Rehabilitation Information Center (NARIC)
4200 Forbes Boulevard
Suite 202
Lanham, MD 20706-4829
naricinfo@heitechservices.com
http://www.naric.com
Tel: 301-459-5900/301-459-5984 (TTY) 800-346-2742
Fax: 301-562-2401

National Stroke Association
9707 East Easter Lane
Suite B
Centennial, CO 80112-3747
info@stroke.org
http://www.stroke.org
Tel: 303-649-9299 800-STROKES (787-6537)
Fax: 303-649-1328

National Institute on Disability and Rehabilitation Research (NIDRR)
U.S. Department of Education Office of Special Education and Rehabilitative Services
400 Maryland Ave., S.W.
Washington, DC 20202-7100
http://www.ed.gov/about/offices/list/osers/nidrr
Tel: 202-245-7460 202-245-7316 (TTY)


Related NINDS Publications and Information

* Traumatic Brain Injury: Hope Through Research
A booklet about traumatic brain injury (TBI), or head injury, prepared by the National Institute of Neurological Disorders and Stroke (NINDS).
*
Clinical Trials in Head Injury
Summary of a workshop, Clinical Trials in Head Injury, held May 12 and 13, 2000
*
NINDS Shaken Baby Syndrome Information Page
Shaken baby syndrome information sheet compiled by the National Institute of Neurological Disorders and Stroke (NINDS).

Publicaciones en Español

* El Traumatismo Cerebral: Esperanza en la Investigación



Prepared by:
Office of Communications and Public Liaison
National Institute of Neurological Disorders and Stroke
National Institutes of Health
Bethesda, MD 20892


NINDS health-related material is provided for information purposes only and does not necessarily represent endorsement by or an official position of the National Institute of Neurological Disorders and Stroke or any other Federal agency. Advice on the treatment or care of an individual patient should be obtained through consultation with a physician who has examined that patient or is familiar with that patient's medical history.

All NINDS-prepared information is in the public domain and may be freely copied. Credit to the NINDS or the NIH is appreciated.

Last updated December 30, 2008


http://www.cdc.gov/ncipc/tbi/TBI.htm
National Center for Injury Prevention and Control
What is Traumatic Brain Injury?

A traumatic brain injury (TBI) is caused by a blow or jolt to the head or a penetrating head injury that disrupts the normal function of the brain. Not all blows or jolts to the head result in a TBI. The severity of a TBI may range from “mild,” i.e., a brief change in mental status or consciousness to “severe,” i.e., an extended period of unconsciousness or amnesia after the injury.




How many people have TBI?

TBIs contribute to a substantial number of deaths and cases of permanent disability annually.

Of the 1.4 million who sustain a TBI each year in the United States:

* 50,000 die;
* 235,000 are hospitalized; and
* 1.1 million are treated and released from an emergency department.1

Among children ages 0 to 14 years, TBI results in an estimated:

* 2,685 deaths;
* 37,000 hospitalizations; and
* 435,000 emergency department visits annually.1

The number of people with TBI who are not seen in an emergency department or who receive no care is unknown.

For more information about TBI in the United States, including the groups at highest risk, CDC’s surveillance activities, and the numbers of TBI cases in each state, see Overview.
Featured Resources
Help Seniors Live Better, Longer: Prevent Brain Injury

Heads Up: Concussion in High School Sports

Heads Up: Concussion in Youth Sports


Heads Up: Brain Injury in Your Practice


Traumatic Brain Injury in the United States: Emergency Department Visits, Hospitalizations, and Deaths


Research Findings on Treatment Guidelines for Severe TBI


Facts about Concussion and Brain Injury and Where to Get Help
CDC Study Finds Traumatic Brain Injuries Can Result from Seniors Falls

What causes TBI?

The leading causes of TBI are:

* Falls (28%);
* Motor vehicle-traffic crashes (20%);
* Struck by/against events (19%); and
* Assaults (11%).1

For more information on the leading causes of TBI, see Causes.


What are the signs and symptoms of TBI?

The signs and symptoms of a traumatic brain injury (TBI) can be subtle. Symptoms of a TBI may not appear until days or weeks following the injury or may even be missed as people may look fine even though they may act or feel differently.

For a list of common signs and symptoms of TBI, see Signs and Symptoms.


What are the long-term outcomes of TBI?

CDC estimates that at least 5.3 million Americans, approximately 2% of the U.S. population, currently have a long-term or lifelong need for help to perform activities of daily living as a result of a TBI.2

TBI can cause a wide range of functional changes affecting thinking, sensation, language, and/or emotions. It can also cause epilepsy and increase the risk for conditions such as Alzheimer’s disease, Parkinson’s disease, and other brain disorders that become more prevalent with age.3

To learn more about the potential outcomes of TBI, see Outcomes.


What are the costs of TBI?

Direct medical costs and indirect costs such as lost productivity of TBI totaled an estimated $60 billion in the United States in 2000.4

References

1. Langlois JA, Rutland-Brown W, Thomas KE. Traumatic brain injury in the United States: emergency department visits, hospitalizations, and deaths. Atlanta (GA): Centers for Disease Control and Prevention, National Center for Injury Prevention and Control; 2004.


2. Thurman D, Alverson C, Dunn K, Guerrero J, Sniezek J. Traumatic brain injury in the United States: a public health perspective. Journal of Head Trauma and Rehabilitation 1999;14(6):602–15.


3. National Institute of Neurological Disorders and Stroke. Traumatic brain injury: hope through research. Bethesda (MD): National Institutes of Health; 2002 Feb. NIH Publication No.: 02–158.


4. Finkelstein E, Corso P, Miller T and associates. The Incidence and Economic Burden of Injuries in the United States. New York (NY): Oxford University Press; 2006.




Contact
Information

National Center for Injury Prevention and Control
Mailstop F41
4770 Buford Highway NE
Atlanta, GA 30341-3724

Phone: 1-800-CDC-INFO
(1-800-232-4636)
Email: cdcinfo@cdc.gov



This page last modified on March 18, 2009.

Centers for Disease Control and Prevention
National Center for Injury Prevention and Control

Sunday, March 22, 2009

security lapses at Mall of Asia; tips to prevent kids from being poisoned; etc.

Security lapses at SM Mall of Asia, Pasay City.
Because of security lapses at entrances to the following areas at said mall, I could have brought dangerous weapons into said areas: ground floor entrance to SMX Convention Center; second level entrance to what was identfied as Screen Time area; main mall; hypermart.

Tips to prevent children from being poisoned.
http://www.cpsc.gov/cpscpub/prerel/prhtml09/09159.html
NEWS from CPSC
U.S. Consumer Product Safety Commission
Office of Information and Public Affairs Washington, DC 20207
FOR IMMEDIATE RELEASE
March 18, 2009
Release #09-159

“Awareness and action are the keys to preventing unintentional poisonings,” said CPSC Acting Chairman Nancy Nord. “Children act fast. So do poisons. That’s why we urge parents, grandparents and caregivers to have layers of poison prevention protection in the home.”

CPSC recommends that parents and caregivers immediately take these three steps. First, keep medicines and household chemicals in their original, child-resistant containers. Second, store the potentially hazardous substances up and out of a child’s sight and reach. And lastly, keep the National toll-free poison control center telephone number, 800-222-1222, handy in case of a poison emergency.

Additional poison prevention tips to check . . .

* When hazardous products are in use, never let young children out of your sight, even if you must take them along when answering the phone or doorbell.

* Keep items closed and in their original containers.

* Leave the original labels on all products, and read the label before using.

* Always leave the light on when giving or taking medicine so that you can see what you are taking. Check the dosage every time.

* Avoid taking medicine in front of children. Refer to medicine as "medicine," not "candy."

* Clean out the medicine cabinet periodically and safely dispose of unneeded and outdated medicines.

* Do not put decorative lamps and candles that contain lamp oil where children can reach them. Lamp oil can be very toxic if ingested by young children.


Desktop Computers Recalled By Acer America Corp. Due to Overheating, Burn Hazard
http://www.cpsc.gov/cpscpub/prerel/prhtml09/09731.html

Recall Alert
U.S. Consumer Product Safety Commission
Office of Information and Public Affairs Washington, DC 20207
March 19, 2009
Alert #09-731
Desktop Computers Recalled By Acer America Corp. Due to Overheating, Burn Hazard

The following product safety recall was voluntarily conducted by the firm in cooperation with the CPSC. Consumers should stop using the product immediately unless otherwise instructed.

Name of Product: Acer Predator Desktop Computers

Units: About 215

Importer: Acer America Corp., of San Jose, Calif.

Hazard: The insulation on the computer’s internal wiring can become bent or stripped, causing the wires to overheat while the product is in use. This poses a burn hazard to consumers.

Incidents/Injuries: Acer has received two reports of computers short circuiting, resulting in melted internal components and external casing. Neither incident occurred in the U.S. No injuries have been reported.

Description: This recall involves Acer Predator desktop computers. The high-end gaming machines have model numbers ASG7200 and ASG7700. Model numbers are printed on the bottom right corner of the panel on the right side of the system.

Sold by: Computer and electronic stores nationwide from May 2008 through December 2008 for between $2,000 and $6,000.

Manufactured in: China

Remedy: Consumers should immediately stop using these recalled computers and contact Acer to schedule a free repair.

Consumer Contact: For additional information, contact Acer toll-free at (866) 695-2237 anytime, or visit the firm’s Web site at www.acer.com




customer advisory re Xin Tian Di restaurant
whose address was identified as Crowne Plaza Galleria Manila, Ortigas Avenue cor. Asian Development Bank Avenue, Quezon City The July 10, 2008 issue of the
Philippine Star newspaper contained the following regarding said restaurant: ". . .where diners can choose from over 100 Asian fusion dishes . . . indulge
in a limitless array of Chinese cuisine . . ." For their own benefit, it will be advantageous for customers to, before patronizing said restaurant,
require the manager of said restaurant to provide them, in advance, with: (1) a complete list of the alleged over 100 Asian fusion dishes; (2) proofs, if
any, that said restaurant has a limitless (italicization by the undersigned) array of Chinese cuisine . . ." (3) certification from said manager that,
every Friday and Saturday, said alleged over 100 Asian fusion dishes and alleged limitless array of Chinese cuisine will be available from the time said
restaurant opens up to the time said restaurant closes.

Advisory vs. Wendy's eatery and
Bacolod Chicken Inasal eatery


On September 28, 2008, in Manila, (1) Wendy's eatery in Ermita, near Ermita church, had a men's rest room which did not have visible (to unaided eye), soap and hot water and automatic hand dryer. So, how, could male food preparation personnel and food servers at said eatery wash their hands? So, it would be easier for germs to be transferred to foods and eating utensils.(2) Bacolod Chiceken Inasal eatery at 2nd floor at Robinsons Ermita mall: (1) had eating utensils at tables, exposed to germs, dust, insects; (2) had food servers who, were seen by the undersigned, touching their faces. One of said servers, was seen by the undersigned, touching his hair. One of said servers, was seen by the undersigned, touching the inside of his nose. After that, said servers did not wash/sterilze their hands, at least while the undersigned was at said eatery. Also, there were dead insects on the floor of the dining area of said eatery. Also, the food undersigned ordered was delivered on what was identified as a leaf from a banana plant. Was said leaf sterilized? Also, the plate containing the chicken undersigned ordered had a container touching/in contact with exposed chicken.
So the germs from said container could contaminate said chicken. Proof that I was at said restaurant on said date is Bacolod Chicken Inasal official receipt
No. 11086 dated 9-28-08.

advisory re Tirta Spa, Sitio Malabunot, Manoc-Manoc, Boracay Island, Malay, Aklan
It will benefit potential customers of said spa to, before patronizing said spa,obtain the following information:
(1) a complete list of the services offered by said spa and the prices for said services; (2) proof, if any, that said spa has its own water supply and
power supply; (3) proof if any that spa has appropriately trained employees. An article regarding said spa was published in the November 22, 2008 issue of
the Manila Bulletin newspaper. Said article contained the statement: "ensuring ultimate satisfaction for each client." If a client of said spa is not
ultimately satisfied with the service of said spa, will said spa refund the money said client paid?

Advisory re the Landmark
at Ayala Center, Makati. On November 26, 2008, deadly weapons could have been brought into said building because security guard at an entrance of said building didn't inspect my waist bag, etc., which were large enough to contain said objects. In the afternoon of said date, I asked a person, at what was identified as the customer service of the Landmark supermarket , to show me the lane for senior citizens at said store. She pointed to two lanes at said store, but said lanes did not bear any visible indications that said lanes were for senior citizens. Also an employee of said store, at what was identified as lane 4 of said store, gave me less money change than I was entitled to.


Advisory re Fucoidan Slimming, Rejuvenation & Wellness Center, Bayani Road, Fort Bonifacio, Taguig City. It will benefit the public thinking of patronizing said center, to, before patronizing said center, obtain the following information regarding Fucoidan and said center. Does the manager or owner of said center, who was identified as Marissa del Mar, agree with the claims that Fucoidan (1) benefits range from health, beauty, and even mood elevation? (2) reduces cholesterol, moisturizes the skin, advances the growth of hair, inhibits blood coagulation, and prevents high blood pressure? (3) is anti-cancer and is good for the liver? If so, it will benefit potential customers to require said manager or owner of said center to provide to them, proofs, if any, regarding said alleged benefits. Does the Philippine Bureau of Food and Drug approve of said claims? What are the services offered by said center, the prices for said services and proofs, if any, that the personnel of said center are qualified to perform said services.

Warning vs. Sun Cellular
store at Robinsons Place Ermita. Based on my records, I sent, on September 19, 2008, a letter via registered mail addressed to said store. Said letter was
designated as registered letter No. 7960. Based on the registry return receipt for said letter, said letter was received, on September 26, 2008, by the
manager of said store. Up to March 21, 2009, I have not received any reply regarding said letter from anyone from said store. Said letter contained the following words:
" On September 17, 2008, an ad of Sun Cellular featuring Nokia 2600c and Nokia 2630 cellular phones was published on page D-1 of the September 17, 2008
issue of the Philippine Star newspaper. For the benefit of the public, please provide soonest to me the following information regarding said phones: the
talk times and standby times; how much radiation is emitted."

Advisory re mobile phone with SMART Communications SIM. On November 19, 2008, the following message appeared in said phone: "You have a minimum of 41 minutes worth of local calls or 951 available SMS".
However, after I loaded 300 pesos worth into said phone, the following message appeared in said phone: "Your current balance is P613.50 and 671 free text msgs."

customer advisory regarding Jollibee restaurant and Chow King restaurant which were at P. Gil St., near corner Paz St.

customer advisory regarding PLDT WeROAM service.

public service advisory concerning Nora Dela Rosa clinic
with address identified as G/F, 427 Martinez St., Mandaluyong City.








Information from:
U. S. Food and Drug Administration
Center for Food Safety and Applied Nutrition
Office of Cosmetics and Colors
information regarding hypoallergenic cosmetics



"HYPOALLERGENIC COSMETICS

Hypoallergenic cosmetics are products that manufacturers claim produce fewer allergic reactions than other cosmetic products. Consumers with hypersensitive skin, and even those with "normal" skin, may be led to believe that these products will be gentler to their skin than non-hypoallergenic cosmetics.

There are no Federal standards or definitions that govern the use of the term "hypoallergenic." The term means whatever a particular company wants it to mean. Manufacturers of cosmetics labeled as hypoallergenic are not required to submit substantiation of their hypoallergenicity claims to FDA.

The term "hypoallergenic" may have considerable market value in promoting cosmetic products to consumers on a retail basis, but dermatologists say it has very little meaning."

http://www.cfsan.fda.gov/~dms/cos-224.html
U. S. Food and Drug Administration Center for Food Safety and Applied Nutrition
Office of Cosmetics and Colors Fact Sheet December 19, 1994; revised October 18, 2000

Friday, March 20, 2009

Warning vs. SM Harrison Plaza Manila; web sites with useful information

warning vs. SM Harrison Plaza, Mla.
On November 3, 2007, security lapse occurred at an entrance to SM Harrison Plaza, Manila. I have evidence that, on said date, an employee at said store, received a written report regarding said security lapse.
Up to March 20, 2009 I have not received any reply from anyone from SM regarding said report.


web sites with useful, free information:

visualmakeover web site
http://www.visual-makeover.com/

storycorps net web site
http://www.storycorps.net/

NationalGeographic blogs
http://ngm.typepad.com/national_geographic_blogs/

http://ngm.typepad.com/digital_photography/
Digital Photography

National Geographic Visions of Earth
http://ngm.nationalgeographic.com/visions-of-earth/visions-earth-2008

lancet com
http://www.lancet.com/

http://www.articlesbase.com/

tripmama web site
http://www.tripmama.com/default.aspx?tabid=159

SF examiner web site
http://www.examiner.com/

National Institute On Alcohol Abuse and Alcoholism
http://www.niaaa.nih.gov/

National Highway Traffic Safety Administration
http://www.nhtsa.gov/

MSN Encarta Online Encyclopedia_Dictionary_Atlas and Homework
http://encarta.msn.com/

Merriam Webster Online
http://www.merriam-webster.com/cgi-bin/mwwod.pl

goodguide web site
http://www.goodguide.com/

Tuesday, March 17, 2009

2nd customer security advisory vs. SM Makati; DTI-NCR; web sites with useful information

2nd customer security advisory vs. SM Makati
at Ayala Center, Makati City. On October 14, 2007, a person, identified as an employee, identified as "Jenete" of SM Department store at SM Makati, received from me a written report regarding a security lapse on October 14, 2007, at a second level entrance to SM Makati. Said lapse occurred at approximately 12:30 A.M. of said date. Up to March 17, 2009, I have not received any communication from anyone from SM regarding said security lapse.

DTI-NCR received advisories vs. : Ecowaste Coalition,
SM City Manila, Abenson Superstore, and Octagon store
Evidence is a letter bearing the following:
"dti DEPARTMENT OF TRADE & INDUSTRY
PHILIPPINES LEGAL AFFAIRS CENTER February
26, 2009 . . .Dear Mr. Silva, This is to acknowledge receipt
of of the Advisories you sent to this Office against the
following: 1. Ecowaste Coalition, 2. SM City Manila,
3. Abenson Superstore, and 4. Octagon Store . . .
Asst. Sec. MA. THERESA L. PELAYO-TY
National Capital Region Regional Operations Group . . ."
The advisory vs. SM City Manila concerned security lapse at entrance to said mall. Because of said security lapse, I could have brought deadly weapons into
said building. Abenson Superstore was in Quezon City. The Octagon store was at Robinson Ermita.

For users/owners of Canon G10 cameras. I strongly suggest you search web sites of makers of said camera for firmware update for said cameras.

Barnes & Noble web site
http://www.barnesandnoble.com/bestsellers/top10everything.asp?z=y

European Food Safety Authority
http://www.efsa.europa.eu/EFSA/efsa_locale-1178620753812_home.htm

govengine web site
http://www.govengine.com/

JAMA_The Journal of the American Medical Association
http://jama.ama-assn.org/

tommys org web site
http://www2.tommys.org/Page.aspx?pid=191


USDA/ARS Children's Nutrition Research Center at Baylor College of Medicine
http://www.kidsnutrition.org/

Friday, March 13, 2009

March 13, 2009 security lapses at entrances to shopping areas at SM Mall of Asia; web sites with useful, free information

On March 13, 2009 security lapses occurred at entrances to different shopping areas at SM Mall of Asia. Details and evidence available.

public service advisory vs. Alex Magno and St. Luke's Medical Center
The following words were published under the words: "By ALEX MAGNO" on page 10 of the March 5, 2009 issue of the Philippine Star newspaper. Evidence available.

"St. Luke's . . . Anyone who materializes at the hospital seeking
medical attention will get it."

If someone materializes at said hospital seeking medical attention but does not get it, will said Magno compensate them/help them?


In 2008, I sent registered letter to said hospital requesting for information regarding said hospital. Based on evidence, said letter was received in 2008 by an authorized agent of said hospital. Up to March 13, 2009, I have not received
any reply from anyone connected with said hospital.

customer advisory re Caesars coffeeshop
at Makati Palace hotel, P. Burgos St., Makati City. It will benefit potential customers of said coffeeshop, to obtain the following information about said store before patronizing said store:
(1) proof, if any, that every day that said eatery is open, there is at least one person on duty who has been trained in proper handling of food;
(2) the complete name(s) of the cook(s) at said eatery and complete details of said cook(s) educational background(s) and experience in cookery
(3) proofs, if any, that said eatery has adequate refrigeration/freezing equipment; (4)proofs, if any, that the management follows the proper methods of
disposal of food wastes; (5)proofs, if any, that said restaurant has sufficient, fully charged and properly placed appropriate type of fire extinguishers;
(6) a complete list of foods offered by said restaurant and the prices of said foods; (7) a complete list of the specialties (if any) of said restaurant
(8) proofs, if any, that said eatery, has in place adequate procedures to prevent food poisoning;


web sites with useful, free information:

aarpmagazine
http://www.aarpmagazine.org/

Dewantoro Network
http://www.dewantoro.net/

AHRQ Effective Health Care Program
http://effectivehealthcare.ahrq.gov/

The Effective Health Care Program is dedicated to facilitating decision making by providing findings from high-quality research in formats for different audiences.

For consumers:9 guides
Treating Prostate Cancer: A Guide for Men With Localized Prostate Cancer Available as Audio

Consumer Summary Guide published 24 Jul 2008


Pills for Type 2 Diabetes: A Guide for Adults Tambien esta disponible en Español Available as Audio

Consumer Summary Guide published 5 Dec 2007


Gastroesophageal Reflux Disease (GERD) Tambien esta disponible en Español

Consumer Summary Guide published 13 Dec 2005


Comparing Two Kinds of Blood Pressure Pills: ACEIs and ARBs

Consumer Summary Guide published 1 Nov 2007


Renal Artery Stenosis Treatments

Consumer Summary Guide published 26 Jun 2007


Antidepressant Medicines - A Guide for Adults With Depression Available as Audio

Consumer Summary Guide published 15 Aug 2007


Choosing Pain Medicine For Osteoarthritis Tambien esta disponible en Español Available as Audio

Consumer Summary Guide published 10 Jan 2007


Osteoporosis Treatments That Help Prevent Broken Bones: A Guide for Women After Menopause Available as Audio

Consumer Summary Guide published 11 Jun 2008


Rheumatoid Arthritis Medicines: A Guide for Adults Available as Audio

Consumer Summary Guide published 9 Apr 2008


Research Reviews Research Reviews Icon

Research reviews from the Effective Health Care initiative are reported in several formats. Comparative Effectiveness Reviews (CERs) and Effectiveness Reviews aim to provide comprehensive appraisal and synthesis of evidence. Updates apply systematic methods to bring CERs and Evidence Reviews up to date by reviewing the current literature. Technical Briefs aim to provide an overview of key issues related to an emerging diagnostic or therapeutic intervention. All research reviews are produced by the Evidence-based Practice Centers. To be notified when new Research Reviews become available, join our e-mail list.
Health Condition

* Cancer
* Diabetes
* Digestive system conditions
* Heart and blood vessel conditions
* Mental health
* Muscle, bone, and joint conditions

Research Methodology

* Research Methodology

Cancer3 final reports
Comparative Effectiveness and Safety of Radiotherapy Treatments for Head and Neck Cancer

Draft Key Questions published 17 Aug 2007
Comment Period closed on 14 Sep 2007

Research in Progress — Draft Due January - March 2009

Comparative Effectiveness of Therapies for Clinically Localized Prostate Cancer

Final Research Review published 5 Feb 2008

Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment

Final Research Review published 23 May 2006

Effectiveness of Noninvasive Diagnostic Tests for Breast Abnormalities

Final Research Review published 9 Feb 2006

Technical Brief: Particle Beam Radiation Therapies for Cancer

Draft Research Review published 15 Jul 2008




Diabetes2 final reports
Comparative Effectiveness and Safety of Oral Diabetes Medications for Adults With Type 2 Diabetes

Final Research Review published 16 Jul 2007

Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes

Final Research Review published 15 Sep 2008




Digestive system conditions1 final report
Comparative Effectiveness of Management Strategies for Gastroesophageal Reflux Disease

Final Research Review published 13 Dec 2005




Heart and blood vessel conditions4 final reports
Comparative Effectiveness of Medical Therapies with or without ACEs or ARBs for Stable Ischemic Heart Disease

Draft Key Questions published 2 Feb 2008
Comment Period closed on 3 Mar 2008

Research in Progress — Draft Due April - July 2009

Comparative Effectiveness of Management Strategies for Renal Artery Stenosis

Final Research Review published 24 Oct 2006

Comparative Effectiveness of Management Strategies for Renal Artery Stenosis: 2007 Update

Final Research Review published 19 Nov 2007

Comparative Effectiveness of Percutaneous Coronary Interventions and Coronary Artery Bypass Grafting for Coronary Artery Disease

Final Research Review published 15 Oct 2007

Effectiveness and Off-label Use of Recombinant Factor VIIa

Draft Key Questions published 28 Sep 2007
Comment Period closed on 26 Oct 2007

Research in Progress — Draft Due February - May 2009

Technical Brief: Percutaneous Heart Valves

Key Questions published 8 Jul 2008

Research in Progress — Draft Due January - March 2009

Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin II Receptor Antagonists (ARBs) for Treating Essential Hypertension

Final Research Review published 1 Nov 2007




Mental health2 final reports
Comparative Effectiveness of Non-Pharmacologic Treatments for Refractory Depression

Draft Key Questions published 2 Dec 2008
Comment Period closed on 30 Dec 2008

Research in Progress

Comparative Effectiveness of Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression

Final Research Review published 24 Jan 2007

Efficacy and Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics

Final Research Review published 17 Jan 2007

Traumatic Brain Injury and Depression

Draft Key Questions published 2 Dec 2008
Comment Period closed on 30 Dec 2008

Research in Progress




Muscle, bone, and joint conditions3 final reports
Comparative Effectiveness of Drug Therapy for Rheumatoid Arthritis and Psoriatic Arthritis in Adults

Final Research Review published 19 Nov 2007

Comparative Effectiveness of Non-operative and Operative Treatments for Rotator Cuff Tears

Draft Key Questions published 11 Aug 2008
Comment Period closed on 9 Sep 2008

Research in Progress

Comparative Effectiveness of Treatments To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis

Final Research Review published 17 Dec 2007

Comparative Effectiveness and Safety of Analgesics for Osteoarthritis

Final Research Review published 25 Sep 2006




Research Methodology2 ics
Methods Guide for Comparative Effectiveness Reviews

Work in Progress — Last updated 18 Nov 2008

Assessing the Need to Update Comparative Effectiveness Research Reviews

Abstract published 7 Jul 2008

Work in Progress — Draft Due December 2008-February 2009




New Research New Research Icon

New Research reports cover new evidence and analytical tools. They are produced by the DEcIDE Research Network and the Centers for Education & Research on Therapeutics (CERTs). To get notified when New Research becomes available, join our e-mail list.

Background information about DEcIDE research projects and a figure describing project stages and product development timelines is available in the About Us ? DEcIDE section of the website.
Health Condition

* Brain and nerve conditions
* Breathing conditions
* Cancer
* Diabetes
* Digestive system conditions
* Heart and blood vessel conditions
* Infectious diseases and HIV/AIDS
* Mental health
* Muscle, bone, and joint conditions

Research Methodology

* Research methodology

Brain and nerve conditions1 ic
Methods for Studying Dementia Treatment and Outcomes in Observational Databases

Final Research Report published 22 May 2008


Breathing conditions4 ics
Comparative Effects of Classes of Antidepressants on the Risk of Aspiration Pneumonia in the Aged

Final Research Report published 22 May 2008

Community Pharmacy/Call Center Assessment of Medication Effectiveness & Safety

Research Abstract published 15 Nov 2005

Research in Progress

Comparative Effectiveness of Anticholinergic Medications in Patients with Chronic Obstructive Pulmonary Disease (COPD)

Research Abstract published 7 Aug 2007

Research in Progress

Outcomes of COPD Management

Research Abstract published 12 Oct 2005

Research in Progress


Cancer3 ics
Advancing Research Methodology for Measuring and Monitoring Patient-Centered Communications in Cancer Care

Research Abstract published 26 Sep 2007

Research in Progress

Computer-based Clinical Decision Support (CDS) Tools for Gene-based Tests Used in Breast Cancer

Research Abstract published 22 Sep 2008

Research in Progress

Testing Cancer Quality Measures for End of Life Care

Research Abstract published 17 Oct 2006

Research in Progress


Diabetes4 ics
A Case Control Study to Assess Association of Variations in OCT Genes with Effectiveness of Metformin in Diabetic Patients

Research Abstract published 30 May 2008

Research in Progress

Addressing Knowledge Gaps in Type 2 Diabetes Therapeutics: Comparative Effectiveness and Safety of Oral Antidiabetic Drugs

Research Abstract published 18 Nov 2008

Research in Progress

Comparative Effectiveness and Safety of New Therapies for Glucose Control in Diabetes Mellitus

Research Abstract published 12 Oct 2005

Research in Progress

Comparative Effectiveness of Oral Hypoglycemics for Reducing Diabetic Nephropathy

Research Abstract published 30 Oct 2008

Research in Progress


Digestive system conditions1 ic
Comparative Safety of NSAIDs with Gastroprotective Therapy

Research Abstract published 15 Nov 2005

Research in Progress


Heart and blood vessel conditions10 ics
Comparative Effectiveness of B-Adrenergic Antagonists on the Risk of Rehospitalization in Adults with Diagnosed Heart Failure

Final Research Report published 30 Nov 2007

A Multicenter, Observational Cohort Study to Assess the Cardiovascular Risks of Medications Prescribed for Attention Deficit Hyperactivity Disorder

Research Abstract published 18 Sep 2007

Research in Progress

A Qualitative Study to Understand Barriers to Conducting Cluster Randomized Trials

Research Abstract published 15 Nov 2005

Research in Progress

Addressing Knowledge Gaps in the Treatment of Hypertension Using ACE/ARB Therapies

Research Abstract published 28 Oct 2008

Research in Progress

Bridging Knowledge Gaps in the Comparative Effectiveness of ACE Inhibitors and ARBs

Research Abstract published 30 Oct 2008

Research in Progress

Development of a Software Tool for Obtaining Doubly Robust Estimate of Treatment Effects

Research Abstract published 15 Nov 2005

Research in Progress

Development of Statistical Estimators to Address Questions of Comparative Effectiveness in Elderly Heart Failure Patients

Research Abstract published 15 Nov 2005

Research in Progress

Medical Management of Congestive Heart Failure and the Effectiveness of Isosorbide Dinitrate and Hydralazine

Research Abstract published 12 Oct 2005

Research in Progress

Research on Optimal Second-Line Therapy for Hypertension

Research Abstract published 18 Oct 2006

Research in Progress

Treatment of In-Stent Restenosis

Research Abstract published 12 Oct 2005

Research in Progress


Infectious diseases and HIV/AIDS1 ic
MRSA Reservoirs in Hospitals and Nursing Homes

Research Abstract published 14 Jan 2009

Research in Progress


Mental health5 ics
Comparative Effects of Classes of Antidepressants on the Risk of Aspiration Pneumonia in the Aged

Final Research Report published 22 May 2008

Comparative Safety of Conventional and Atypical Antipsychotic Medications: Risk of Death in British Columbia Seniors

Final Research Report published 29 Aug 2007

A Multicenter, Observational Cohort Study to Assess the Cardiovascular Risks of Medications Prescribed for Attention Deficit Hyperactivity Disorder

Research Abstract published 18 Sep 2007

Research in Progress

A Qualitative Study to Understand Barriers to Conducting Cluster Randomized Trials

Research Abstract published 15 Nov 2005

Research in Progress

Addressing Knowledge Gaps in the Treatment of Depression

Research Abstract published 23 Oct 2008

Research in Progress


Muscle, bone, and joint conditions4 ics
Assessment of Factors Modulating Treatment Outcomes of Rheumatoid Arthritis

Final Research Report published 30 Oct 2008

Adaptation of Data Mining Algorithms Assessing the Comparative Effectiveness and Safety of NSAIDs

Research Abstract published 15 Nov 2005

Research in Progress

Comparative Safety of Analgesics for Arthritis

Research Abstract published 27 Oct 2008

Research in Progress

Comparative Safety of NSAIDs with Gastroprotective Therapy

Research Abstract published 15 Nov 2005

Research in Progress


Research methodology19 ics
Emerging Methods in Comparative Effectiveness and Safety - Medical Care Supplement

Final Research Report published 25 Sep 2007

Infrastructure to Monitor Utilization and Outcomes of Gene-Based Applications: An Assessment

Final Research Report published 21 May 2008

Medicare Prescription Drug Data Development: Methods for Improving Patient Safety and Pharmacovigilance Using Observational Data

Final Research Report published 26 Aug 2008

Registries for Evaluating Patient Outcomes: A User's Guide

Final Research Report published 16 May 2007

Survey of Medicare Part D Plans' Medication Therapy Management Programs

Final Research Report published 16 Mar 2007

A Qualitative Study to Understand Barriers to Conducting Cluster Randomized Trials

Research Abstract published 15 Nov 2005

Research in Progress

Adaptation of Data Mining Algorithms Assessing the Comparative Effectiveness and Safety of NSAIDs

Research Abstract published 15 Nov 2005

Research in Progress

Assessing the Validity of Administrative Data Using Clinical Medical Records

Research Abstract published 15 Nov 2005

Research in Progress

Community Pharmacy/Call Center Assessment of Medication Effectiveness & Safety

Research Abstract published 15 Nov 2005

Research in Progress

Data Development for Patient Safety -- A Pilot Study using Medicare Part B Drug Data

Research Abstract published 12 Oct 2005

Research in Progress

Developing a Distributed Research Network to Conduct Population-based Studies and Safety Surveillance

Research Abstract published 10 Jan 2008

Research in Progress

Development and Validation of Instrumental Variable Methods for Effectiveness Research

Research Abstract published 14 May 2007

Research in Progress

Development of a Software Tool for Obtaining Doubly Robust Estimate of Treatment Effects

Research Abstract published 15 Nov 2005

Research in Progress

Development of Statistical Estimators to Address Questions of Comparative Effectiveness in Elderly Heart Failure Patients

Research Abstract published 15 Nov 2005

Research in Progress

Distributed Network for Ambulatory Research in Therapeutics

Research Abstract published 10 Jan 2008

Research in Progress

Needs Assessment to Establish an Infrastructure for Monitoring the Utilization and Outcomes of Gene-Based Applications in the United States Health Care System

Research Abstract published 3 Aug 2007

Research in Progress

Registries for Evaluating Patient Outcomes Version II

Research Abstract published 18 Nov 2008

Research in Progress

Research and Surveillance Methods for Improving Medication Safety Using Administrative Claims Databases

Research Abstract published 12 Oct 2005

Research in Progress

Testing Cancer Quality Measures for End of Life Care

Research Abstract published 17 Oct 2006

Research in Progress

Saturday, March 7, 2009

books with useful info; U.S. Supreme Court re Wyeth Corp,: web sites with free useful info

books with useful information:
Mayo Clinic Guide to Self-Care
The Urban Survival Handbook
Wash Your Hands!
Help Me Heal
What You Don't Know Can Kill You
Health Smart Hospital Handbook
What's In This Stuff?

U.S. Supreme Court re Wyeth Corporation
The following was obtained from what was identified as the website of the U.S. Supreme Court:

"SUPREME COURT OF THE UNITED STATES
Syllabus
WYETH v. LEVINE
CERTIORARI TO THE SUPREME COURT OF VERMONT
http://www.supremecourtus.gov/opinions/08pdf/06-1249.pdf

No. 06–1249. Argued November 3, 2008—Decided March 4, 2009
Petitioner Wyeth manufactures the antinausea drug Phenergan. After a clinician injected respondent Levine with Phenergan by the “IV-push” method, whereby a drug is injected directly into a patient’s vein, the drug entered Levine’s artery, she developed gangrene, and doctors amputated her forearm. Levine brought a state-law damages action, alleging, inter alia, that Wyeth had failed to provide an ade-quate warning about the significant risks of administering Phener-gan by the IV-push method. The Vermont jury determined that Le-vine’s injury would not have occurred if Phenergan’s label included an adequate warning, and it awarded damages for her pain and suf-fering, substantial medical expenses, and loss of her livelihood as aprofessional musician. Declining to overturn the verdict, the trial court rejected Wyeth’s argument that Levine’s failure-to-warn claims were pre-empted by federal law because Phenergan’s labeling had been approved by the federal Food and Drug Administration (FDA). The Vermont Supreme Court affirmed.
Held: Federal law does not pre-empt Levine’s claim that Phenergan’slabel did not contain an adequate warning about the IV-push method of administration. Pp. 6–25.
(a) The argument that Levine’s state-law claims are pre-empted because it is impossible for Wyeth to comply with both the state-lawduties underlying those claims and its federal labeling duties is re-jected. Although a manufacturer generally may change a drug labelonly after the FDA approves a supplemental application, the agency’s“changes being effected” (CBE) regulation permits certain preap-proval labeling changes that add or strengthen a warning to improve drug safety. Pursuant to the CBE regulation, Wyeth could have uni-laterally added a stronger warning about IV-push administration, and there is no evidence that the FDA would ultimately have rejected."


web sites with useful free information:

ABC news wellness center
http://abcnews.go.com/health/wellness

Audubon web site
http://www.audubon.org/

doctorpundit web site
http://www.doctorpundit.com/

Modis web site
http://modis.gsfc.nasa.gov/gallery/index.php

Thursday, March 5, 2009

Have children's flip flops containing decorative paint and made in Brazil been imported into the Philippines?

Have children's flip flops containing decorative paint and made in Brazil been imported into the Philippines?

The following was obtained from the the U.S. government web site Consumer Product Safety Commission
"Children’s Flip Flops Recalled by Alpargatas Due to Violation of Lead in Paint Standard
http://www.cpsc.gov/cpscpub/prerel/prhtml09/09137.html

News from CPSC
U.S. Consumer Product Safety Commission
Office of Information and Public Affairs Washington, DC 20207
FOR IMMEDIATE RELEASE
March 3, 2009
Release # 09-137 Firm’s Recall Hotline: (888) 289-5306
CPSC Recall Hotline: (800) 638-2772p
CPSC Media Contact: (301) 504-7908
Children’s Flip Flops Recalled by Alpargatas Due to Violation of Lead in Paint Standard
WASHINGTON, D.C. - The U.S. Consumer Product Safety Commission, in cooperation with the firm named below, today announced a voluntary recall of the following consumer product. Consumers should stop using recalled products immediately unless otherwise instructed.

Name of product: Children’s flip flops

Units: About 210,000

Manufacturer: Alpargatas USA Inc., of New York, N.Y.

Hazard: Decorative paint on the sole of the flip flops can contain levels of lead in excess of the federal standard.

Incidents/Injuries: None reported

Description: Flip flops of the Havaianas brand containing decorative paint were sold under the following model names:
Baby Estampas, Baby Pets, Kids Apple, Kids Fairy, Kids Flores, Kids Lighthouse, Kids Monsters, Kids Surf, Baby Letrinhas,
Kids Sports, Kids Candies, Kids Fun, Kids Love, Kids Sereias, Kids Speed, Kids Lucky Bug, Kids Pets, Kids Rock, Kids Slim,
Kids Wonder Woman, Kids Small Flowers and Kids Tropical w/Kit. Havaianas flip flops without decorative paint are not being
recalled.

Sold by: Department and specialty stores nationwide from November 2006 through February 2009 for about $15 to $24 a pair.

Manufactured in: Brazil

Remedy: Consumers should immediately take the recalled flip flops away from children and return them to Alpargatas USA, Inc.
to receive a replacement."



web sites with free,useful information:

BBC News Online medical notes library
http://news.bbc.co.uk/2/hi/health/medical_notes/default.stm

cancerresearch uk
http://www.cancerresearchuk.org/

Federation of American Societies for Experimental Biology
http://www.faseb.org/

health nytimes
http://health.nytimes.com/pages/health/index.html

Nature Genetics
http://www.nature.com/ng/

Paging Dr. Gupta blog
http://pagingdrgupta.blogs.cnn.com/

image of registry return receipt of letter addressed to Makati councilor J. J. Binay

image of registry return receipt of letter addressed to Makati councilor J. J. Binay